Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
25.50
-1.50 (-5.56%)
Nov 6, 2026, 3:06 PM EST - Market open
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Arcutis Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $39.13. The average 1-year stock price forecast is 53.45% higher than the current stock price, while the lowest is $34 (+33.33%) and the highest is $48 (+88.24%).
Price Target: $39.13 (+53.45%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +56.86% | Nov 5, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $38 | Buy | Maintains | $38 | +49.02% | Nov 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $40 | Buy | Reiterates | $40 | +56.86% | Nov 5, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $38 → $44 | Buy | Reiterates | $38 → $44 | +72.55% | Oct 19, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $48 | Buy | Initiates | $48 | +88.24% | Oct 15, 2026 |
Financial Forecast
Revenue This Year
538.56M
from 376.07M
Increased by 43.21%
Revenue Next Year
695.69M
from 538.56M
Increased by 29.18%
EPS This Year
0.43
from -0.13
EPS Next Year
1.34
from 0.43
Increased by 214.90%
EPS and Forward PE are based on non-GAAP adjusted numbers.